"As one of the top eye centers in the country, the Duke Eye Center treats more than 175,000 people each year and offers the full spectrum of eye care. Duke Eye Center's expert ophthalmologists offer comprehensive eye care services to Durham, North Carolina and the surrounding areas."

During the past decade, Duke Eye Center conducted 74 clinical trials. In the 10-year time frame, 74 clinical trials started and 30 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 18 clinical trials were completed. i.e. 54.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke Eye Center" #1 sponsor was "Duke University" with 32 trials, followed by "Jaeb Center for Health Research" with 16 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Lux Biosciences, Inc." with 5 trials sponsored and "Applied Genetic Technologies Corp" with 5 trials sponsored. Other sponsors include 46 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke Eye Center" #1 collaborator was "National Eye Institute (NEI)" with 23 trials as a collaborator, "Bausch & Lomb Incorporated" with 7 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 6 trials as a collaborator, "Foundation Fighting Blindness" with 4 trials as a collaborator and "Duke University" with 3 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Duke Eye Center" are "Glaucoma" (14 trials), "Amblyopia" (6 trials), "Retinopathy of Prematurity" (6 trials), "Diabetic Macular Edema" (5 trials) and "Diabetic Retinopathy" (5 trials). Many other conditions were trialed in "Duke Eye Center" in a lesser frequency.

Most popular intervention types in "Duke Eye Center" are "Drug" (58 trials), "Device" (29 trials), "Other" (16 trials), "Procedure" (6 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Bevacizumab" (3 trials), "LX211" (3 trials), "Atropine" (2 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Duke Eye Center" are 109 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are 34 active trials in "Duke Eye Center". 2 are not yet recruiting, 14 are recruiting, 15 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 58 completed trials in Duke Eye Center, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Duke Eye Center, 13 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 27 trials that are defined as “Not Applicable".